169 related articles for article (PubMed ID: 12695132)
1. Skin manifestations in CD4+, CD56+ malignancies.
Penven K; Macro M; Salaun V; Comoz F; Reman O; Leroy D; Troussard X; Petrella T; Dompmartin A
Eur J Dermatol; 2003; 13(2):161-5. PubMed ID: 12695132
[TBL] [Abstract][Full Text] [Related]
2. Cutaneous CD4+ CD56+ hematologic malignancies.
Magro CM; Porcu P; Schaefer J; Erter JW; Furman RR; Shitabata PK; Crowson AN
J Am Acad Dermatol; 2010 Aug; 63(2):292-308. PubMed ID: 20541283
[TBL] [Abstract][Full Text] [Related]
3. TCL1 and CLA expression in agranular CD4/CD56 hematodermic neoplasms (blastic NK-cell lymphomas) and leukemia cutis.
Petrella T; Meijer CJ; Dalac S; Willemze R; Maynadié M; Machet L; Casasnovas O; Vergier B; Teitell MA
Am J Clin Pathol; 2004 Aug; 122(2):307-13. PubMed ID: 15323148
[TBL] [Abstract][Full Text] [Related]
4. CD4+ CD56+ hematodermic neoplasm.
Cibull TL; Thomas AB; O'Malley DP; Billings SD
Am J Dermatopathol; 2007 Feb; 29(1):59-61. PubMed ID: 17284963
[TBL] [Abstract][Full Text] [Related]
5. CD4+ CD56+ hematodermic neoplasm and plasmacytoid dendritic cell tumor: case report and review of the literature.
Campbell SM; Moad JC; Sammons DL; Zirwas M
Cutis; 2012 Jun; 89(6):278-83. PubMed ID: 22838092
[TBL] [Abstract][Full Text] [Related]
6. CD4+/CD56+ haematodermic neoplasm: a preculsor haematological neoplasm that frequently first presents in the skin.
Martín JM; Nicolau MJ; Galán A; Ferrández-Izquierdo A; Ferrer AM; Jordá E
J Eur Acad Dermatol Venereol; 2006 Oct; 20(9):1129-32. PubMed ID: 16987271
[TBL] [Abstract][Full Text] [Related]
7. Blastic natural killer cell lymphoma/leukemia (CD56-positive blastic tumor): prognostication and categorization according to anatomic sites of involvement.
Suzuki R; Nakamura S; Suzumiya J; Ichimura K; Ichikawa M; Ogata K; Kura Y; Aikawa K; Teshima H; Sako M; Kojima H; Nishio M; Yoshino T; Sugimori H; Kawa K; Oshimi K;
Cancer; 2005 Sep; 104(5):1022-31. PubMed ID: 15999368
[TBL] [Abstract][Full Text] [Related]
8. CD56(+) TdT(+) blastic natural killer cell tumor of the skin: a primitive systemic malignancy related to myelomonocytic leukemia.
Khoury JD; Medeiros LJ; Manning JT; Sulak LE; Bueso-Ramos C; Jones D
Cancer; 2002 May; 94(9):2401-8. PubMed ID: 12015765
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical analysis of CD123, CD56 and CD4 for the diagnosis of minimal bone marrow involvement by blastic plasmacytoid dendritic cell neoplasm.
Hwang K; Park CJ; Jang S; Chi HS; Huh JR; Lee JH; Suh C; Lee KH
Histopathology; 2013 Apr; 62(5):764-70. PubMed ID: 23470050
[TBL] [Abstract][Full Text] [Related]
10. CD4+/CD56+ hematodermic neoplasm: report of a rare variant with a T-cell receptor gene rearrangement.
Stetsenko GY; McFarlane R; Kalus A; Olerud J; Cherian S; Fromm J; George E; Argenyi Z
J Cutan Pathol; 2008 Jun; 35(6):579-84. PubMed ID: 18005171
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous tumors as the initial presentation of non-T, non-B, nonmyeloid CD4+ CD56+ hematolymphoid malignancy in an adolescent boy.
Fass J; Tichy EH; Kraus EW; Herrick JL; Ehsan A; Peterson J; Grimwood RE
Pediatr Dermatol; 2005; 22(1):19-22. PubMed ID: 15660891
[TBL] [Abstract][Full Text] [Related]
12. CD4+CD56+ hematodermic neoplasms bear a plasmacytoid dendritic cell phenotype.
Urosevic M; Conrad C; Kamarashev J; Asagoe K; Cozzio A; Burg G; Dummer R
Hum Pathol; 2005 Sep; 36(9):1020-4. PubMed ID: 16153467
[TBL] [Abstract][Full Text] [Related]
13. Lacking CD56 expression in a relapsing cutaneous blastic plasmacytoid dendritic cell neoplasm after allogeneic bone marrow transplantation: FISH analysis revealed loss of 11q.
Mitteldorf C; Bertsch HP; Baumgart M; Haase D; Wulf G; Schön MP; Rosenwald A; Neumann C; Kaune KM
J Eur Acad Dermatol Venereol; 2011 Oct; 25(10):1225-9. PubMed ID: 21923812
[TBL] [Abstract][Full Text] [Related]
14. CD56+ lymphoma with skin involvement: clinicopathologic features and classification.
Gniadecki R; Rossen K; Ralfkier E; Thomsen K; Skovgaard GL; Jønsson V
Arch Dermatol; 2004 Apr; 140(4):427-36. PubMed ID: 15096371
[TBL] [Abstract][Full Text] [Related]
15. CD4+/CD56+ hematodermic tumor: the features of an evolving entity and its relationship to dendritic cells.
Herling M; Jones D
Am J Clin Pathol; 2007 May; 127(5):687-700. PubMed ID: 17439829
[TBL] [Abstract][Full Text] [Related]
16. CD4+/CD56+ hematodermic neoplasm: presentation of 2 cases and review of the concept of an uncommon tumor originated in plasmacytoid dendritic cells expressing CD123 (IL-3 receptor alpha).
Piña-Oviedo S; Herrera-Medina H; Coronado H; Del Valle L; Ortiz-Hidalgo C
Appl Immunohistochem Mol Morphol; 2007 Dec; 15(4):481-6. PubMed ID: 18091395
[TBL] [Abstract][Full Text] [Related]
17. CD4+/CD56+ hematodermic neoplasm ("blastic natural killer cell lymphoma"): neoplastic cells express the immature dendritic cell marker BDCA-2 and produce interferon.
Pilichowska ME; Fleming MD; Pinkus JL; Pinkus GS
Am J Clin Pathol; 2007 Sep; 128(3):445-53. PubMed ID: 17709319
[TBL] [Abstract][Full Text] [Related]
18. Cutaneous CD4+/CD56+ hematodermic neoplasm.
Zindanci I; Kavala M; Buyukbabani N; Kocaturk E; Koc M
Indian J Dermatol Venereol Leprol; 2010; 76(6):723. PubMed ID: 21079332
[TBL] [Abstract][Full Text] [Related]
19. Primary cutaneous blastic plasmacytoid dendritic cell neoplasm without extracutaneous manifestation: case report and review of the literature.
Li Y; Li Z; Lin HL; Chen XH; Li B
Pathol Res Pract; 2011 Jan; 207(1):55-9. PubMed ID: 20573459
[TBL] [Abstract][Full Text] [Related]
20. Primary cutaneous small/medium CD4+ T-cell lymphomas: a heterogeneous group of tumors with different clinicopathologic features and outcome.
Garcia-Herrera A; Colomo L; Camós M; Carreras J; Balague O; Martinez A; Lopéz-Guillermo A; Estrach T; Campo E
J Clin Oncol; 2008 Jul; 26(20):3364-71. PubMed ID: 18541895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
